Published in Br J Cancer on June 08, 2010
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One (2011) 1.89
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer (2014) 1.59
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol (2011) 1.59
Targeting BRAF for patients with melanoma. Br J Cancer (2010) 1.56
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol (2014) 1.55
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45
Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res (2011) 1.40
Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol (2011) 1.37
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene (2013) 1.25
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ (2012) 1.24
Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J (2012) 1.18
Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm (2011) 1.17
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies. Clin Cancer Res (2011) 1.01
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res (2013) 0.93
The evolution of S100B inhibitors for the treatment of malignant melanoma. Future Med Chem (2013) 0.91
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep (2012) 0.90
Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett (2015) 0.88
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res (2014) 0.88
What is new in the treatment of advanced melanoma? State of the art. Contemp Oncol (Pozn) (2012) 0.88
GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. J Invest Dermatol (2012) 0.87
Therapeutic options in cutaneous melanoma: latest developments. Ther Adv Med Oncol (2011) 0.87
Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways. Pigment Cell Melanoma Res (2011) 0.87
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res (2014) 0.87
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol (2016) 0.86
Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia (2013) 0.86
The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol (2012) 0.86
Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res (2011) 0.85
In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. Adv Drug Deliv Rev (2013) 0.85
Functional analysis and molecular targeting of aurora kinases a and B in advanced melanoma. Genes Cancer (2010) 0.85
An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance. Cancer Discov (2013) 0.84
Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11. Pigment Cell Melanoma Res (2012) 0.84
Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. Oncotarget (2011) 0.84
A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics (2015) 0.83
Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr Mol Med (2011) 0.83
New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist (2014) 0.83
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics (2014) 0.82
Specifically targeting ERK1 or ERK2 kills melanoma cells. J Transl Med (2012) 0.82
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. Clin Exp Metastasis (2012) 0.81
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget (2016) 0.80
The GIST of targeted therapy for malignant melanoma. Ann Surg Oncol (2014) 0.80
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. Oncologist (2017) 0.80
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Oncogene (2016) 0.79
BRAF and beyond: Tailoring strategies for the individual melanoma patient. J Carcinog (2014) 0.79
A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Mol Cancer (2011) 0.79
Targeted therapy for melanoma: is double hitting a home run? Nat Rev Clin Oncol (2012) 0.79
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol (2014) 0.78
Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma. Expert Opin Investig Drugs (2011) 0.78
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. Elife (2015) 0.78
Targeted Therapies in Melanoma: Translational Research at Its Finest. J Invest Dermatol (2015) 0.78
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Devel Ther (2015) 0.77
Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Onco Targets Ther (2013) 0.77
BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Mol Cancer Ther (2015) 0.76
The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Mol Cancer Ther (2015) 0.76
Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Med Chem Lett (2014) 0.76
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol (2016) 0.75
Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer. J Thorac Dis (2016) 0.75
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. EMBO Mol Med (2016) 0.75
Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol (2017) 0.75
Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. Chonnam Med J (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Targeted cancer therapy. Nature (2004) 7.81
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res (2008) 2.57
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer (2003) 2.37
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene (2007) 1.84
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene (2005) 1.83
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer (2007) 1.57
Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res (2007) 1.50
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene (2005) 1.20
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia (2005) 1.18
Effects of atmosphere of incubation and of routine subcultures on detection of bacteremia in vacuum blood culture bottles. J Clin Microbiol (1975) 5.78
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Comparison of two liquid blood culture media containing sodium polyanethole sulfonate: tryptic soy and Columbia. Appl Microbiol (1974) 4.52
Detection of bacteremia with liquid media containing sodium polyanetholsulfonate. Appl Microbiol (1974) 4.41
Recovery of yeast from vented blood culture bottles. J Clin Microbiol (1975) 3.42
Near misses: a useful adjunct to maternal death enquiries. Br Med Bull (2003) 3.26
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry (1995) 2.72
A centimeter here, a centimeter there: does it matter? J Am Acad Dermatol (1995) 2.67
Conservation. Reconsidering the consequences of selective fisheries. Science (2012) 2.57
Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest (1998) 2.53
New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J (1971) 2.45
Evaluation of a routine anaerobic subculture of blood cultures for detection of anaerobic bacteremia. J Clin Microbiol (1978) 2.44
Atlanto-axial subluxation and cervical myelopathy in rheumatoid arthritis. Q J Med (1971) 2.20
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry (1997) 2.10
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg (1999) 2.02
A signal sequence is not sufficient to lead beta-galactosidase out of the cytoplasm. Nature (1980) 2.00
Application of 16S rRNA gene PCR to study bowel flora of preterm infants with and without necrotizing enterocolitis. J Clin Microbiol (1996) 2.00
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99
An outbreak of Salmonella saint-paul infection associated with beansprouts. Epidemiol Infect (1990) 1.79
Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol (1995) 1.76
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res (2000) 1.74
The premature breech: trial of labor or cesarean section? Obstet Gynecol (1979) 1.70
Is antenatal care apportioned according to obstetric risk? The Scottish antenatal care study. J Public Health Med (1994) 1.68
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Dying from cancer in community hospitals or a hospice: closest lay carers' perceptions. Br J Gen Pract (1998) 1.66
Upconverting phosphor reporters in immunochromatographic assays. Anal Biochem (2001) 1.61
Evaluation of molecular methodologies and rabbit infectivity testing for the diagnosis of congenital syphilis and neonatal central nervous system invasion by Treponema pallidum. J Infect Dis (1993) 1.60
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer (2007) 1.57
Clinical birthweight standards for a total population in the 1980s. Br J Obstet Gynaecol (1993) 1.56
Passive protective properties of serum fractions from mice inoculated with an anti-pseudomonas vaccine. Immunology (1972) 1.56
Association of human papillomavirus and colon neoplasms. Arch Surg (1990) 1.55
Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell Melanoma Res (2010) 1.55
High density lipoprotein metabolism in man. J Clin Invest (1977) 1.53
Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects. J Lipid Res (1978) 1.53
Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds. Br J Dermatol (2003) 1.51
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil. Clin Oncol (R Coll Radiol) (2002) 1.44
Progress and problems in defining susceptibility genes for rheumatic diseases. Rheumatology (Oxford) (2002) 1.42
Guidelines in gynaecology: evaluation in menorrhagia and in urinary incontinence. BJOG (2000) 1.41
The great cabbage hoax: a case study. J Pers Soc Psychol (1965) 1.41
Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology (1996) 1.41
Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer (1996) 1.41
Control and intrusive memories as possible determinants of chronic stress. Psychosom Med (1993) 1.40
Urinary tract injuries during obstetric intervention. Br J Obstet Gynaecol (1997) 1.40
Orthopaedics Overseas: first world MDs can make a difference in the Third World. CMAJ (1990) 1.39
Congenital uro-nephropathies: is routine voiding cystourethrography always warranted? Clin Radiol (1998) 1.39
Evaluation of electronic discussion groups as a teaching/learning strategy in an evidence-based medicine course: a pilot study. Educ Health (Abingdon) (2001) 1.39
Escherichia coli O157 incident associated with a farm open to members of the public. Commun Dis Public Health (1999) 1.39
Effects of water supplementation on physiological jaundice in breast-fed babies. Arch Dis Child (1981) 1.38
Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol (1997) 1.36
Identification of pathological mineral deposits by Raman microscopy. Lancet (1991) 1.32
Measuring and comparing constraints to improved biosecurity amongst GB farmers, veterinarians and the auxiliary industries. Prev Vet Med (2008) 1.30
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation (1999) 1.29
Measurement properties of performance-based measures to assess physical function in hip and knee osteoarthritis: a systematic review. Osteoarthritis Cartilage (2012) 1.29
Palliative terminal cancer care in community hospitals and a hospice: a comparative study. Br J Gen Pract (1998) 1.27
Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study. J Bone Miner Res (1995) 1.26
Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. EMBO J (1997) 1.25
Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiol Drug Saf (2012) 1.20
Age-related differences in breast cancer treatment. Ann Surg Oncol (1994) 1.18
cDNA cloning and pattern of expression of an adult, female-specific chymotrypsin from Aedes aegypti midgut. Insect Biochem Mol Biol (1997) 1.18
Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol (1997) 1.17
Radiographic pelvimetry for assessment of dystocia in bitches: a clinical study in two terrier breeds. J Small Anim Pract (1999) 1.16
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest (1998) 1.14
"Something moving in my head". Lancet (1999) 1.11
Rhodopsin in the rod outer segment plasma membrane. J Cell Biol (1976) 1.11
The role of MR imaging for the assessment of complicated duplex kidneys in children: preliminary report. Pediatr Radiol (2001) 1.10
Cell division in Deinococcus radiodurans and a method for displaying septa. Can J Microbiol (1983) 1.09
Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res (1984) 1.09
Sleep and treatment response in depression: new findings using power spectral analysis. Psychiatry Res (2001) 1.08
Major therapeutic developments and current challenges in advanced melanoma. Br J Dermatol (2014) 1.07
Sleep in the wake of complicated grief symptoms: an exploratory study. Biol Psychiatry (1997) 1.06
Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am (1999) 1.06
Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects. Br J Pharmacol (2008) 1.05
Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer (1984) 1.04
Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res (1993) 1.02
Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol (1997) 1.01
CT of recurrent retroperitoneal sarcomas. AJR Am J Roentgenol (2000) 1.01
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol (2012) 1.01
Characterization of a clotting protein, isolated from plasma of the freshwater crayfish Pacifastacus leniusculus. Eur J Biochem (1993) 1.01
Insulin inhibits growth hormone signaling via the growth hormone receptor/JAK2/STAT5B pathway. J Biol Chem (1999) 1.00
Confirmation of the association of human papillomavirus with human colon cancer. Am J Surg (1993) 1.00
The gravity suit: a major advance in management of gynecologic blood loss. Obstet Gynecol (1979) 1.00
Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J Immunol (1997) 1.00
Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg (1998) 0.99
Changes in the molecular composition of circulating hydroxyethyl starch. Br J Pharmacol (1970) 0.99
The effects of opiate receptor agonists and antagonists on the stress-induced secretion of corticosterone in mice. Br J Pharmacol (1979) 0.98
Causes and methods to estimate cryptic sources of fishing mortality. J Fish Biol (2013) 0.98
Development of memory for pattern and path: further evidence for the fractionation of visuo-spatial memory. Q J Exp Psychol A (2001) 0.97
Malignant melanoma of the foot and ankle. J Bone Joint Surg Am (1995) 0.97
Quality indicators for the prevention of type 2 diabetes in Europe--IMAGE. Horm Metab Res (2010) 0.97
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer (2001) 0.97
Low-glycemic index diet in hyperlipidemia: use of traditional starchy foods. Am J Clin Nutr (1987) 0.97